810222C

C6-NBD Glucosyl Ceramide

Avanti Research^™ - A Croda Brand 810222C

• Synonym(e): N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-glucosyl-β1-1′-sphingosine
• Empirische Formel (Hill-System): C₃₆H₅₉N₅O₁₁
• CAS-Nummer: 94885-03-7
• Molekulargewicht: 737.88
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Assay: >99% (TLC)
• Form: liquid
• Verpackung: pkg of 1 × 1 mL (810222C-250ug); pkg of 1 × 1 mg (81022C-1MG)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 810222C
• Konzentration: 0.25 mg/mL (810222C-250ug)
• Versandbedingung: dry ice
• Lagertemp.: −20°C

Beschreibung

Allgemeine Beschreibung

C6-NBD Glucosyl Ceramide is a fluorescent derivative of biologically active compound, glucosyl ceramide. Glucosyl ceramide belongs to the class of sphingolipids that are synthesized in the cis/medial-Golgi apparatus by the glycosylation of ceramide.

Anwendung

C6-NBD Glucosyl Ceramide may be used as a substrate for glucocerebrosidase (GCase) activity assay in Drosophila melanogaster and mice.

Biochem./physiol. Wirkung

Glucosylceramide is the precursor of different glycosphingolipids including gangliosides and sulfatides. Glucosyl ceramide is also known to be responsible for axon growth of neural cells. The accumulation of glucosyl ceramide is associated with an inherited lysosomal storage disorder, Gaucher′s disease.

Verpackung

5 mL Amber Glass Screw Cap Vial (81022C-1MG)

5 mL Clear Glass Sealed Ampule (810222C-250ug)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Piktogramme: GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H302,H315,H319,H331,H336,H351,H361d,H372
• P-Sätze: P201 - P260 - P264 - P280 - P304 + P340 + P311 - P403 + P233
• Gefahreneinstufungen: Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3
• Zielorgane: Central nervous system
• WGK: WGK 3